BRPI0510612A - derivados de (1,10b-diidro-2-(aminocarbonil-fenil)-5h-pirazol[1,5-c][ 1,3]-benzoxazin-5-il)fenil metanona como inibidores de replicação viral do hiv - Google Patents

derivados de (1,10b-diidro-2-(aminocarbonil-fenil)-5h-pirazol[1,5-c][ 1,3]-benzoxazin-5-il)fenil metanona como inibidores de replicação viral do hiv

Info

Publication number
BRPI0510612A
BRPI0510612A BRPI0510612-5A BRPI0510612A BRPI0510612A BR PI0510612 A BRPI0510612 A BR PI0510612A BR PI0510612 A BRPI0510612 A BR PI0510612A BR PI0510612 A BRPI0510612 A BR PI0510612A
Authority
BR
Brazil
Prior art keywords
phenyl
benzoxazin
viral replication
pyrazol
present
Prior art date
Application number
BRPI0510612-5A
Other languages
English (en)
Inventor
Abdellah Tahri
Lieve Emma Jan Michiels
Koenraad Lodewijk August Acker
Dominique Louis Nest Surleraux
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of BRPI0510612A publication Critical patent/BRPI0510612A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

DERIVADOS DE (1,10B-DIIDRO-2-(AMINOCAR-BONIL-FENIL)-5H-PIRAZOL¢1,5-C!¢ 1,3!BENZOXAZIN-5-IL)FENIL METANONA COMO INIBIDORES DE REPLICAçãO VIRAL DO HIV. A presente invenção refere-se a derivados de 5H-pirazol¢1,5-c!¢1,3!benzoxazin-5-il)fenil metanona como inibidores da replicação viral do vírus HIV, processos para sua preparação, bem como composições farmacêuticas, seu uso como medicamentos, e kits de diagnóstico que os contêm. A presente invenção também se refere a combinações dos presentes inibidores de HIV com outros agentes anti-retrovirais. Refere-se adicionalmente a seu uso em testes como compostos de referência ou como reagentes. Os compostos da presente invenção são úteis para evitar ou tratar infecção por HIV e para tratar AIDS.
BRPI0510612-5A 2004-05-04 2005-05-04 derivados de (1,10b-diidro-2-(aminocarbonil-fenil)-5h-pirazol[1,5-c][ 1,3]-benzoxazin-5-il)fenil metanona como inibidores de replicação viral do hiv BRPI0510612A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04101913 2004-05-04
US60427504P 2004-08-25 2004-08-25
PCT/EP2005/052041 WO2005105810A2 (en) 2004-05-04 2005-05-04 (1,10b-dihydro-2-(aminocarbonyl-phenyl)-5h-pyrazolo[1,5- c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as hiv viral replication inhibitors

Publications (1)

Publication Number Publication Date
BRPI0510612A true BRPI0510612A (pt) 2007-10-30

Family

ID=35058129

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510612-5A BRPI0510612A (pt) 2004-05-04 2005-05-04 derivados de (1,10b-diidro-2-(aminocarbonil-fenil)-5h-pirazol[1,5-c][ 1,3]-benzoxazin-5-il)fenil metanona como inibidores de replicação viral do hiv

Country Status (20)

Country Link
US (1) US7326703B2 (pt)
EP (1) EP1778696B1 (pt)
JP (1) JP4929162B2 (pt)
KR (1) KR20070015547A (pt)
CN (1) CN1950380B (pt)
AP (1) AP2006003759A0 (pt)
AR (1) AR048650A1 (pt)
AT (1) ATE389660T1 (pt)
AU (1) AU2005238235B2 (pt)
BR (1) BRPI0510612A (pt)
CA (1) CA2563959C (pt)
DE (1) DE602005005490T2 (pt)
ES (1) ES2303244T3 (pt)
IL (1) IL178082A (pt)
MX (1) MXPA06012755A (pt)
NO (1) NO20065582L (pt)
PL (1) PL1778696T3 (pt)
RU (1) RU2382789C2 (pt)
WO (1) WO2005105810A2 (pt)
ZA (1) ZA200609178B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
TW200710091A (en) * 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
JP2009514790A (ja) * 2005-07-22 2009-04-09 プロジェニクス・ファーマスーティカルズ・インコーポレイテッド Ｈｉｖ−１−感染患者におけるウイルス負荷を減少させる方法
BRPI0812964A2 (pt) * 2007-06-25 2014-12-16 Tibotec Pharm Ltd Forma de dosagem farmacêutica oral sólida
US8592487B2 (en) * 2007-10-26 2013-11-26 Concert Pharmaceuticals, Inc. Deuterated darunavir
WO2009134401A2 (en) * 2008-04-29 2009-11-05 Progenics Pharmaceuticals, Inc. Methods of inhibiting infection by diverse subtypes of drug-resistant hiv-1

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE4210939A1 (de) * 1992-04-02 1993-10-07 Bayer Ag Verwendung von 7-Oxo-7H-pyrido[1,2,3-de][1,4]benzoxacin-6-carbonsäuren und -estern als Arzneimittel
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
WO1995009615A1 (en) 1993-10-01 1995-04-13 Astra Aktiebolag Process i
EP0904060B1 (en) 1996-05-20 2003-12-10 Janssen Pharmaceutica N.V. Antifungal compositions with improved bioavailability
WO1998014436A1 (en) * 1996-10-02 1998-04-09 Dupont Pharmaceuticals Company 4,4-disubstituted-1,4-dihydro-2h-3,1-benzoxazin-2-ones useful as hiv reverse transcriptase inhibitors and intermediates and processes for making the same
SI0969821T1 (en) 1997-03-26 2003-10-31 Janssen Pharmaceutica N.V. Pellets having a core coated with an antifungal and a polymer
SK17482000A3 (sk) * 1998-05-20 2005-03-04 Eli Lilly And Company Antivírusové zlúčeniny, spôsob inhibície vírusov a farmaceutický prípravok
DE60219292T2 (de) * 2001-04-10 2008-04-10 Pfizer Inc. Pyrazolderivate zur behandlung von hiv

Also Published As

Publication number Publication date
ZA200609178B (en) 2008-08-27
ATE389660T1 (de) 2008-04-15
RU2006142705A (ru) 2008-06-20
EP1778696B1 (en) 2008-03-19
RU2382789C2 (ru) 2010-02-27
IL178082A (en) 2012-06-28
CA2563959C (en) 2014-07-15
ES2303244T3 (es) 2008-08-01
AP2006003759A0 (en) 2006-10-31
PL1778696T3 (pl) 2008-08-29
CN1950380B (zh) 2010-12-08
CA2563959A1 (en) 2005-11-10
NO20065582L (no) 2006-12-04
AR048650A1 (es) 2006-05-10
JP2007536346A (ja) 2007-12-13
KR20070015547A (ko) 2007-02-05
DE602005005490D1 (de) 2008-04-30
MXPA06012755A (es) 2007-01-16
US7326703B2 (en) 2008-02-05
EP1778696A2 (en) 2007-05-02
AU2005238235A1 (en) 2005-11-10
DE602005005490T2 (de) 2009-04-23
US20070248624A1 (en) 2007-10-25
JP4929162B2 (ja) 2012-05-09
WO2005105810A2 (en) 2005-11-10
IL178082A0 (en) 2006-12-31
WO2005105810A3 (en) 2006-03-02
AU2005238235B2 (en) 2011-07-07
CN1950380A (zh) 2007-04-18

Similar Documents

Publication Publication Date Title
Li et al. The natural viral load profile of patients with pandemic 2009 influenza A (H1N1) and the effect of oseltamivir treatment
Madani Alkhumra virus infection, a new viral hemorrhagic fever in Saudi Arabia
BRPI0517463A (pt) inibidores da protease do vìrus da hepatite c, composições e tratamentos usando os mesmos
Ferraris et al. Evaluation of Crimean-Congo hemorrhagic fever virus in vitro inhibition by chloroquine and chlorpromazine, two FDA approved molecules
BRPI0510612A (pt) derivados de (1,10b-diidro-2-(aminocarbonil-fenil)-5h-pirazol[1,5-c][ 1,3]-benzoxazin-5-il)fenil metanona como inibidores de replicação viral do hiv
BR112022026321A2 (pt) Análogos de 1'-ciano nucleosídeo e usos dos mesmos
BRPI0513196A (pt) formulações tópicas antivirais
BRPI0410418A (pt) fenil quinolinas e seu uso como moduladores do receptor de estrogênio
WO2008017692A3 (en) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
BRPI1011540A2 (pt) anticorpos anticxcr4 para o tratamento de of hiv
ATE552852T1 (de) Zusammensetzungen und verfahren zur behandlung von virusinfektionen
BRPI0410563B8 (pt) compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas
BR0306993A (pt) Polìmero de polialquilenoglicol ativado; composição farmacêutica; método para tratar um paciente que tem uma infecção viral suscetìvel; e método para tratar um paciente suspeito de ter infecção por hepatite c
BRPI0518994A2 (pt) anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
BRPI0713443A2 (pt) Derivados de piperazinila úteis no tratamento de doenças medianas por receptor gpr38, uso e composição farmacêutica contendo tais compostos e processos para preparação dos mesmos
CO6390077A2 (es) Inhibidores de hacv ns5a
TR201815272T4 (tr) İnfluenza virüs replikasyonu inhibitörleri.
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
BRPI0407306A (pt) 1,2,4- triazinas de inibição de hiv
BRPI0514724A (pt) inibidores da enzima hiv integrase
BRPI0519148A2 (pt) inibidores de homodimerizaÇço de myd88
BRPI0511778A (pt) derivados da naftalina úteis como ligantes do receptor 3 da histamina
BRPI0407591A (pt) inibidores de transcriptase reversa de não-nucleosìdeo
UA95715C2 (ru) Фосфадиазиновые производные, фармацевтическая композиция и их применение
Williams et al. Δ 9-Tetrahydrocannabinol Treatment during Human Monocyte Differentiation Reduces Macrophage Susceptibility to HIV-1 Infection

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.